Clementia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CMTA)

$12.30 +0.38 (+3.19 %)
(As of 02/21/2018 06:12 AM ET)
Previous Close$11.92
Today's Range$12.00 - $12.72
52-Week Range$11.72 - $20.15
Volume37,100 shs
Average Volume81,571 shs
Market Capitalization$363.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals logoClementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio12.71%
Quick Ratio12.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net Income$-57,510,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-211.59%

Miscellaneous

Employees24
Outstanding Shares30,530,000

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

When will Clementia Pharmaceuticals make its next earnings announcement?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Clementia Pharmaceuticals.

Where is Clementia Pharmaceuticals' stock going? Where will Clementia Pharmaceuticals' stock price be in 2018?

4 analysts have issued 1 year target prices for Clementia Pharmaceuticals' stock. Their forecasts range from $23.00 to $32.00. On average, they expect Clementia Pharmaceuticals' share price to reach $27.00 in the next twelve months. View Analyst Ratings for Clementia Pharmaceuticals.

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:

  • David Bonita M.D., Chairman of the Board (Age 41)
  • Clarissa Desjardins Ph.D., Chief Executive Officer, Founder, Director
  • Michael Singer, Chief Financial Officer (Age 50)
  • Eric Grinstead, Chief Commercial Officer
  • Donna Grogan M.D., Chief Medical Officer

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

When did the company's lock-up period expire?

Clementia Pharmaceuticals' lock-up period expired on Monday, January 29th. Clementia Pharmaceuticals had issued 8,000,000 shares in its public offering on August 2nd. The total size of the offering was $120,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Who owns Clementia Pharmaceuticals stock?

Clementia Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include ORBIMED ADVISORS LLC (32.87%), ORBIMED ADVISORS LLC (32.87%), Driehaus Capital Management LLC (2.82%), Sectoral Asset Management Inc (0.25%), Victory Capital Management Inc. (0.11%) and Alps Advisors Inc. (0.11%). View Institutional Ownership Trends for Clementia Pharmaceuticals.

Who sold Clementia Pharmaceuticals stock? Who is selling Clementia Pharmaceuticals stock?

Clementia Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Clementia Pharmaceuticals.

Who bought Clementia Pharmaceuticals stock? Who is buying Clementia Pharmaceuticals stock?

Clementia Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Driehaus Capital Management LLC, Alps Advisors Inc., J. Goldman & Co LP and Victory Capital Management Inc.. View Insider Buying and Selling for Clementia Pharmaceuticals.

How do I buy Clementia Pharmaceuticals stock?

Shares of Clementia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of Clementia Pharmaceuticals stock can currently be purchased for approximately $12.30.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $363.88 million. Clementia Pharmaceuticals employs 24 workers across the globe.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 1375 TRANS-CANADA HIGHWAY SUITE 200, DORVAL A8, H9P 2W8. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Clementia Pharmaceuticals (NASDAQ:CMTA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00$27.00N/A
Price Target Upside: 64.43% upside64.43% upside64.43% upsideN/A

Clementia Pharmaceuticals (NASDAQ:CMTA) Consensus Price Target History

Price Target History for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ:CMTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017WedbushReiterated RatingOutperform$26.00N/AView Rating Details
8/31/2017BTIG ResearchInitiated CoverageBuy -> Buy$32.00LowView Rating Details
8/28/2017Leerink SwannInitiated CoverageOutperform -> Outperform$23.00HighView Rating Details
8/28/2017Morgan StanleyInitiated CoverageOverweight -> Overweight$27.00HighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings History and Estimates Chart

Earnings by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ CMTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018        
11/13/2017Q3 2017($0.31)($1.83)ViewN/AView Earnings Details
8/10/2017Q2 2017($9.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.36)($0.36)($0.36)
Q2 20181($0.38)($0.38)($0.38)
Q3 20181($0.41)($0.41)($0.41)
Q4 20181($0.43)($0.43)($0.43)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Clementia Pharmaceuticals (NASDAQ:CMTA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Clementia Pharmaceuticals (NASDAQ CMTA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines

Source:
DateHeadline
 Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Analysts Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 15 at 12:46 PM
Zacks: Brokerages Anticipate Clementia Pharmaceuticals Inc (CMTA) Will Announce Earnings of -$0.34 Per ShareZacks: Brokerages Anticipate Clementia Pharmaceuticals Inc (CMTA) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - February 10 at 11:08 PM
Clementia to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceClementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:11 AM
Clementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head ContrastClementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - February 4 at 9:08 PM
Clementia Appoints Industry Veteran Pierre Legault to its Board of DirectorsClementia Appoints Industry Veteran Pierre Legault to its Board of Directors
finance.yahoo.com - January 31 at 9:20 AM
Clementia Pharmaceuticals (CMTA) Stock Rating Upgraded by Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 30 at 8:38 PM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Given Average Rating of "Strong Buy" by BrokeragesZacks: Clementia Pharmaceuticals Inc (CMTA) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 7:46 AM
 Analysts Anticipate Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS Analysts Anticipate Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS
www.americanbankingnews.com - January 25 at 1:24 AM
Clementia Pharmaceuticals Incs Lock-Up Period To Expire  on January 29th (NASDAQ:CMTA)Clementia Pharmaceuticals Inc's Lock-Up Period To Expire on January 29th (NASDAQ:CMTA)
www.americanbankingnews.com - January 22 at 1:28 AM
Clementia Pharmaceuticals (CMTA) Downgraded to "Sell" at Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 10:28 PM
 Brokerages Set $27.00 Target Price for Clementia Pharmaceuticals Inc (CMTA) Brokerages Set $27.00 Target Price for Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - January 15 at 5:38 PM
 Analysts Set $27.00 Price Target for Clementia Pharmaceuticals Inc (CMTA) Analysts Set $27.00 Price Target for Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - January 10 at 1:44 AM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 26 at 9:52 AM
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaClementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - December 12 at 9:14 AM
Zacks: Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by AnalystsZacks: Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Analysts
www.americanbankingnews.com - December 11 at 7:14 PM
Form 6-K Clementia Pharmaceutical For: Dec 05Form 6-K Clementia Pharmaceutical For: Dec 05
www.streetinsider.com - December 5 at 5:51 PM
 Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages
www.americanbankingnews.com - November 21 at 11:50 PM
Q4 2017 Earnings Forecast for Clementia Pharmaceuticals Inc. Issued By Wedbush (CMTA)Q4 2017 Earnings Forecast for Clementia Pharmaceuticals Inc. Issued By Wedbush (CMTA)
www.americanbankingnews.com - November 17 at 10:40 PM
Clementia Pharmaceuticals (CMTA) Outperform Rating Reiterated at WedbushClementia Pharmaceuticals' (CMTA) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - November 14 at 4:00 PM
Clementia Reports Third Quarter 2017 Financial Results and Business HighlightsClementia Reports Third Quarter 2017 Financial Results and Business Highlights
finance.yahoo.com - November 13 at 10:35 PM
 Analysts Set $27.00 Target Price for Clementia Pharmaceuticals Inc. (CMTA) Analysts Set $27.00 Target Price for Clementia Pharmaceuticals Inc. (CMTA)
www.americanbankingnews.com - November 6 at 9:58 AM
 Clementia Pharmaceuticals Inc. (CMTA) Given Average Recommendation of "Strong Buy" by Analysts Clementia Pharmaceuticals Inc. (CMTA) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - October 22 at 2:46 AM
Have Investors Already Priced In Healthcare Growth For Clementia Pharmaceuticals Inc (CMTA)?Have Investors Already Priced In Healthcare Growth For Clementia Pharmaceuticals Inc (CMTA)?
finance.yahoo.com - October 20 at 6:50 PM
Zacks: Clementia Pharmaceuticals Inc. (CMTA) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Clementia Pharmaceuticals Inc. (CMTA) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - October 15 at 9:04 AM
Clementia Pharmaceuticals to Participate in Upcoming Investor ConferencesClementia Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 6 at 5:17 PM
Clementia Pharms (CMTA) Quiet Period Will Expire  on September 11thClementia Pharm's (CMTA) Quiet Period Will Expire on September 11th
www.americanbankingnews.com - September 4 at 1:14 AM
 Clementia Pharm (CMTA) Given Consensus Rating of "Strong Buy" by Analysts Clementia Pharm (CMTA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - September 1 at 2:34 PM
Clementia Announces Data Presentations at Upcoming Medical Conferences in SeptemberClementia Announces Data Presentations at Upcoming Medical Conferences in September
finance.yahoo.com - August 31 at 5:14 PM
Clementia Pharm (CMTA) Now Covered by BTIG ResearchClementia Pharm (CMTA) Now Covered by BTIG Research
www.americanbankingnews.com - August 31 at 7:46 AM
Clementia Pharm (CMTA) to Post Q3 2017 Earnings of ($0.32) Per Share, Leerink Swann ForecastsClementia Pharm (CMTA) to Post Q3 2017 Earnings of ($0.32) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - August 30 at 6:50 AM
Equities Analysts Offer Predictions for Clementia Pharms Q3 2017 Earnings (CMTA)Equities Analysts Offer Predictions for Clementia Pharm's Q3 2017 Earnings (CMTA)
www.americanbankingnews.com - August 30 at 6:50 AM
Top Analyst Upgrades and Downgrades: CalAmp, Fiat Chrysler, Lowe’s, Plains All American, Ulta Beauty and Many MoreTop Analyst Upgrades and Downgrades: CalAmp, Fiat Chrysler, Lowe’s, Plains All American, Ulta Beauty and Many More
247wallst.com - August 28 at 4:38 PM
Clementia Announces Closing of Over-Allotment Option in its Initial Public OfferingClementia Announces Closing of Over-Allotment Option in its Initial Public Offering
finance.yahoo.com - August 28 at 4:38 PM
Leerink Swann Begins Coverage on Clementia Pharmaceuticals Inc (CMTA)Leerink Swann Begins Coverage on Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - August 28 at 10:10 AM
Clementia Pharmaceuticals Inc (CMTA) Earns Outperform Rating from Analysts at WedbushClementia Pharmaceuticals Inc (CMTA) Earns Outperform Rating from Analysts at Wedbush
www.americanbankingnews.com - August 28 at 7:48 AM
Clementia Pharmaceuticals Inc (CMTA) Now Covered by Analysts at Morgan StanleyClementia Pharmaceuticals Inc (CMTA) Now Covered by Analysts at Morgan Stanley
www.americanbankingnews.com - August 28 at 7:48 AM
Clementia Pharmaceuticals (CMTA) to Raise $101 Million in IPOClementia Pharmaceuticals (CMTA) to Raise $101 Million in IPO
www.americanbankingnews.com - July 21 at 12:26 PM

SEC Filings

Clementia Pharmaceuticals (NASDAQ:CMTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Clementia Pharmaceuticals (NASDAQ:CMTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Clementia Pharmaceuticals (NASDAQ CMTA) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.